Champions Oncology, Inc. (CSBR) vs Gossamer Bio, Inc. (GOSS)
A side-by-side comparison of Champions Oncology, Inc. and Gossamer Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CSBR
Champions Oncology, Inc.
$5.01HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
GOSS
Gossamer Bio, Inc.
$10.78HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CSBR vs GOSS
growth of $100 · dividends reinvested · last 8yCSBR -54.5% (-9.4%/yr)GOSS -99.3% (-45.8%/yr)CSBR compounded faster over this window
Log scale — wide-divergence pair
CSBR GOSS
CSBR vs GOSS: by the numbers
- •CSBR is the larger company ($70M vs $66M market cap).
- •Both run net losses; CSBR's is the smaller (-1.87% vs -235.00% net margin).
Metrics side by side
Valuation
| Metric | CSBR | GOSS |
|---|---|---|
| Forward P/E | 50.10 | N/A |
| P/S ratio | 1.15 | 1.24 |
| P/B ratio | 17.88 | N/A |
| EV / EBITDA | 261.92 | N/A |
Profitability
| Metric | CSBR | GOSS |
|---|---|---|
| Gross margin | 49.30% | 99.56% |
| Operating margin | -1.72% | -336.81% |
| Net margin | -1.87% | -235.00% |
| ROE | -29.15% | N/A |
| ROIC | -6.75% | N/A |
Growth (annualized)
| Metric | CSBR | GOSS |
|---|---|---|
| Revenue CAGR (5Y) | 7.25% | N/A |
| Total return CAGR (5Y) | -13.07% | -59.51% |
Frequently asked
- How have CSBR and GOSS total returns compared?
- Over the past 5 years, CSBR delivered -13.07% and GOSS delivered -59.51% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.